

To: Carter BloodCare Customers

From: Hospital Relations

Date: April 29, 2020

**Re:** Updates to procurement of COVID-19 Convalescent Plasma

## **Background**

Carter BloodCare is providing COVID-19 convalescent plasma through two pathways – single patient emergency IND (eIND) and expanded access protocol (EAP). The single patient eIND was quickly implemented to meet critical patient needs.

The expanded access protocol pathway was subsequently made available allowing blood centers to recruit recovered patients to donate convalescent plasma without the need for a negative test provided the volunteers had complete resolution of symptoms for 28 days before they donated. Carter BloodCare has been progressively recruiting donors with these qualifications and now has a minimal inventory of convalescent plasma. We are confident that our inventory will increase.

## **Update**

Because of the success realized in establishing a supply of convalescent plasma, the following changes will be made to the <u>single patient eIND pathway</u> effective Wednesday, May 6, 2020:

- A single patient name must be provided on the Physician Request.
- The IND approval number must be listed on the Physician Request Form.
- Please limit the number of referred donors to 2. Only one donor will be drawn.
   The additional donor will only be contacted if the first donor is unable to give two or more usable units.
- The recommended dosage for convalescent plasma should be limited to 2 units.
- Once collected and donor passed all testing requirements, the unit(s) will automatically be shipped to your facility. Units collected under the single eIND will not be stored at Carter BloodCare.
- If you have additional recovered patients interested in donating convalescent plasma, please direct them to <a href="https://www.carterbloodcare.org/plasma-donations-for-treating-covid-19/">https://www.carterbloodcare.org/plasma-donations-for-treating-covid-19/</a>. These units will be made available to the community.

## **Impact to Client**

Please inform staff, medical directors, clinicians, and other impacted parties.

Please do not hesitate to contact us with any questions or concerns.